6 results on '"Brady, Michael"'
Search Results
2. Use and acceptability of salivary hepatitis C virus testing in an English Young Offender Institution.
- Author
-
Candfield, Sophie, Samuel, Mannampallil I, Ritchie, David, McDonald, Candice, Brady, Michael, and Taylor, Chris
- Subjects
HEPATITIS C diagnosis ,CORRECTIONAL institutions ,CRIMINALS ,HEPATITIS viruses ,PATIENT satisfaction ,SALIVA ,VIRAL antibodies ,PATIENTS' attitudes - Abstract
People held in prison are at a high risk of having hepatitis C virus (HCV) and there is a public health drive in the UK to increase HCV testing in prisons and Young Offender Institutions (YOIs), with opt-out testing. There is an oral antibody test for HCV; this project aims to determine its acceptability in an English YOI setting. This project offered HCV oral point-of-care testing (POCT) using the OraQuick® test to 107 male young offenders attending a sexual health service at an English YOI, monitoring HCV positivity and evaluating acceptability. It also investigated young offenders' histories of sexually transmitted infections (STIs) and drug use. Mean age was 19.1 years. A total of 80.4% reported lifetime drug use and 0.9% reported lifetime drug injection. A total of 19.6% reported previous STIs. One patient (0.9%) was positive for HCV on OraQuick® testing. All patients found the POCT acceptable and one stated he would have refused a fingerprick test had it been the only test available for HCV testing. Salivary rapid HCV testing is acceptable among English YOI inmates. It is not as sensitive or specific as standard HCV tests and is more expensive. In our cohort, HCV positivity was low. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.
- Author
-
Dolling, David I., Desai, Monica, McOwan, Alan, Gilson, Richard, Clarke, Amanda, Fisher, Martin, Schembri, Gabriel, Sullivan, Ann K., Mackie, Nicola, Reeves, Iain, Portman, Mags, Saunders, John, Fox, Julie, Bayley, Jake, Brady, Michael, Bowman, Christine, Lacey, Charles J., Taylor, Stephen, White, David, and Antonucci, Simone
- Subjects
HIV ,HIV prevention ,MEN who have sex with men ,TENOFOVIR ,EMTRICITABINE-tenofovir ,HIV infection transmission ,HIV infection epidemiology ,COMPARATIVE studies ,DRUG administration ,HIV infections ,HOMOSEXUALITY ,RESEARCH methodology ,MEDICAL cooperation ,PREVENTIVE health services ,RESEARCH ,RESEARCH funding ,RISK assessment ,TIME ,PILOT projects ,SOCIOECONOMIC factors ,EVALUATION research ,UNSAFE sex ,TREATMENT effectiveness ,DISEASE incidence ,ANTI-HIV agents ,REVERSE transcriptase inhibitors - Abstract
Background: Pre-exposure prophylaxis (PrEP) has proven biological efficacy to reduce the sexual acquisition of the human immunodeficiency virus (HIV). The PROUD study found that PrEP conferred higher protection than in placebo-controlled trials, reducing HIV incidence by 86 % in a population with seven-fold higher HIV incidence than expected. We present the baseline characteristics of the PROUD study population and place the findings in the context of national sexual health clinic data.Methods: The PROUD study was designed to explore the real-world effectiveness of PrEP (tenofovir-emtricitabine) by randomising HIV-negative gay and other men who have sex with men (GMSM) to receive open-label PrEP immediately or after a deferral period of 12 months. At enrolment, participants self-completed two baseline questionnaires collecting information on demographics, sexual behaviour and lifestyle in the last 30 and 90 days. These data were compared to data from HIV-negative GMSM attending sexual health clinics in 2013, collated by Public Health England using the genitourinary medicine clinic activity database (GUMCAD).Results: The median age of participants was 35 (IQR: 29-43). Typically participants were white (81 %), educated at a university level (61 %) and in full-time employment (72 %). Of all participants, 217 (40 %) were born outside the UK. A sexually transmitted infection (STI) was reported to have been diagnosed in the previous 12 months in 330/515 (64 %) and 473/544 (87 %) participants reported ever having being diagnosed with an STI. At enrolment, 47/280 (17 %) participants were diagnosed with an STI. Participants reported a median (IQR) of 10 (5-20) partners in the last 90 days, a median (IQR) of 2 (1-5) were condomless sex acts where the participant was receptive and 2 (1-6) were condomless where the participant was insertive. Post-exposure prophylaxis had been prescribed to 184 (34 %) participants in the past 12 months. The number of STI diagnoses was high compared to those reported in GUMCAD attendees.Conclusions: The PROUD study population are at substantially higher risk of acquiring HIV infection sexually than the overall population of GMSM attending sexual health clinics in England. These findings contribute to explaining the extraordinary HIV incidence rate during follow-up and demonstrate that, despite broad eligibility criteria, the population interested in PrEP was highly selective.Trial Registration: Current Controlled Trials ISRCTN94465371 . Date of registration: 28 February 2013. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
4. 'Do it yourself' sexual health care: the user experience.
- Author
-
Baraitser, Paula, Brown, Kirsty Collander, Gleisner, Zachary, Pearce, Vikki, Kumar, Usha, and Brady, Michael
- Subjects
CLIENTS ,SEXUAL health ,CONTRACEPTION ,SEXUALLY transmitted diseases - Abstract
The article reports on a study which describes the experience of clients who availed of a self-booking system in a walk-in sexual health center located in London, England. It says that the service offered contraception and the management of sexually transmissible infections (STI) through take-home pregnancy tests and tests for chlamydia and gonorrhoeae via condoms dispensed from a free vending machine. The study documented the uptake of the self-management options, presented the attitudes of users towards self-management and identified how the option could lead to sexual health service improvement. It concluded that self-management in clinical centers could free up clinical capacity to a certain degree by identifying those who do not need to see a clinician.
- Published
- 2011
- Full Text
- View/download PDF
5. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
- Author
-
McCormack, Sheena, Dunn, David T., Desai, Monica, Dolling, David I., Gafos, Mitzy, Gilson, Richard, Sullivan, Ann K., Clarke, Amanda, Reeves, Iain, Schembri, Gabriel, Mackie, Nicola, Bowman, Christine, Lacey, Charles J., Apea, Vanessa, Brady, Michael, Fox, Julie, Taylor, Stephen, Antonucci, Simone, Khoo, Saye H., and Rooney, James
- Subjects
- *
RANDOMIZED controlled trials , *EMTRICITABINE-tenofovir , *HIV prevention , *MEN who have sex with men , *PATIENT compliance , *ANTI-HIV agents , *BISEXUALITY , *COMPARATIVE studies , *CONDOMS , *HIV , *HIV infections , *HOMOSEXUALITY , *RESEARCH methodology , *MEDICAL cooperation , *PREVENTIVE health services , *RESEARCH , *RESEARCH funding , *PILOT projects , *EVALUATION research , *UNSAFE sex , *TREATMENT effectiveness - Abstract
Background: Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir-emtricitabine reduces the risk of HIV infection. However, this benefit could be counteracted by risk compensation in users of PrEP. We did the PROUD study to assess this effect.Methods: PROUD is an open-label randomised trial done at 13 sexual health clinics in England. We enrolled HIV-negative gay and other men who have sex with men who had had anal intercourse without a condom in the previous 90 days. Participants were randomly assigned (1:1) to receive daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine (200 mg) either immediately or after a deferral period of 1 year. Randomisation was done via web-based access to a central computer-generated list with variable block sizes (stratified by clinical site). Follow-up was quarterly. The primary outcomes for the pilot phase were time to accrue 500 participants and retention; secondary outcomes included incident HIV infection during the deferral period, safety, adherence, and risk compensation. The trial is registered with ISRCTN (number ISRCTN94465371) and ClinicalTrials.gov (NCT02065986).Findings: We enrolled 544 participants (275 in the immediate group, 269 in the deferred group) between Nov 29, 2012, and April 30, 2014. Based on early evidence of effectiveness, the trial steering committee recommended on Oct 13, 2014, that all deferred participants be offered PrEP. Follow-up for HIV incidence was complete for 243 (94%) of 259 patient-years in the immediate group versus 222 (90%) of 245 patient-years in the deferred group. Three HIV infections occurred in the immediate group (1·2/100 person-years) versus 20 in the deferred group (9·0/100 person-years) despite 174 prescriptions of post-exposure prophylaxis in the deferred group (relative reduction 86%, 90% CI 64-96, p=0·0001; absolute difference 7·8/100 person-years, 90% CI 4·3-11·3). 13 men (90% CI 9-23) in a similar population would need access to 1 year of PrEP to avert one HIV infection. We recorded no serious adverse drug reactions; 28 adverse events, most commonly nausea, headache, and arthralgia, resulted in interruption of PrEp. We detected no difference in the occurrence of sexually transmitted infections, including rectal gonorrhoea and chlamydia, between groups, despite a suggestion of risk compensation among some PrEP recipients.Interpretation: In this high incidence population, daily tenofovir-emtricitabine conferred even higher protection against HIV than in placebo-controlled trials, refuting concerns that effectiveness would be less in a real-world setting. There was no evidence of an increase in other sexually transmitted infections. Our findings strongly support the addition of PrEP to the standard of prevention for men who have sex with men at risk of HIV infection.Funding: MRC Clinical Trials Unit at UCL, Public Health England, and Gilead Sciences. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
6. Predicting 10-year breast cancer mortality risk in the general female population in England: a model development and validation study.
- Author
-
Clift AK, Collins GS, Lord S, Petrou S, Dodwell D, Brady M, and Hippisley-Cox J
- Subjects
- Humans, Female, Cohort Studies, Ethnicity, England epidemiology, Cost-Benefit Analysis, Breast Neoplasms diagnosis
- Abstract
Background: Identifying female individuals at highest risk of developing life-threatening breast cancers could inform novel stratified early detection and prevention strategies to reduce breast cancer mortality, rather than only considering cancer incidence. We aimed to develop a prognostic model that accurately predicts the 10-year risk of breast cancer mortality in female individuals without breast cancer at baseline., Methods: In this model development and validation study, we used an open cohort study from the QResearch primary care database, which was linked to secondary care and national cancer and mortality registers in England, UK. The data extracted were from female individuals aged 20-90 years without previous breast cancer or ductal carcinoma in situ who entered the cohort between Jan 1, 2000, and Dec 31, 2020. The primary outcome was breast cancer-related death, which was assessed in the full dataset. Cox proportional hazards, competing risks regression, XGBoost, and neural network modelling approaches were used to predict the risk of breast cancer death within 10 years using routinely collected health-care data. Death due to causes other than breast cancer was the competing risk. Internal-external validation was used to evaluate prognostic model performance (using Harrell's C, calibration slope, and calibration in the large), performance heterogeneity, and transportability. Internal-external validation involved dataset partitioning by time period and geographical region. Decision curve analysis was used to assess clinical utility., Findings: We identified data for 11 626 969 female individuals, with 70 095 574 person-years of follow-up. There were 142 712 (1·2%) diagnoses of breast cancer, 24 043 (0·2%) breast cancer-related deaths, and 696 106 (6·0%) deaths from other causes. Meta-analysis pooled estimates of Harrell's C were highest for the competing risks model (0·932, 95% CI 0·917-0·946). The competing risks model was well calibrated overall (slope 1·011, 95% CI 0·978-1·044), and across different ethnic groups. Decision curve analysis suggested favourable clinical utility across all age groups. The XGBoost and neural network models had variable performance across age and ethnic groups., Interpretation: A model that predicts the combined risk of developing and then dying from breast cancer at the population level could inform stratified screening or chemoprevention strategies. Further evaluation of the competing risks model should comprise effect and health economic assessment of model-informed strategies., Funding: Cancer Research UK., Competing Interests: Declaration of interests SL reports institutional funding for clinical trials for which they are the Chief Investigator or Principal Investigator from Cancer Research UK, Boehringer Ingelheim, Piqur Therapeutics, AstraZeneca, Carrick Therapeutics, Sanofi, Merck, Synthon, Roche, and UK National Institute for Health and Care Research (NIHR); consulting fees from Sanofi, GLG Consulting, Rejuversen, Oxford Biodynamics; payment or honoraria for lectures or presentations from Esai, Prosigna, Roche, Pfizer, Novartis and Sanofi; personal support for attending meetings or for travel from Pfizer, Roche, Synthon and Piqur therapeutics; is a co-founder of MitoRx therapeutics; research funding from Cancer Research UK, Against Breast Cancer, Pathios Therapeutics, and NIHR; and participation on a data safety monitoring board or advisory board for Shionogi. JH-C is an unpaid director of QResearch and is a founder and shareholder of ClinRisk and was its medical director until May 31, 2019; and reports other grant support from the Wellcome Trust and the John Fell Fund. All other authors declare no competing interests., (Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.